United States Patent 10,076,555: Claim Scope, Exclusivity, Litigation Risk and Patent Landscape for Afamelanotide

U.S. Patent No. 10,076,555 protects a narrow clinical-use profile for afamelanotide, also known as [Nle4, D-Phe7]-alpha-MSH. The claims require a human treatment, induction of epidermal melanogenesis, a sustained-release delivery system, and a defined low-plasma-exposure profile. The patent does not broadly cover every use of afamelanotide, every melanogenesis treatment, or every implant formulation.

The principal commercial product implicated by the claims is Clinuvel Pharmaceuticals’ Scenesse, an afamelanotide subcutaneous implant approved by the FDA for erythropoietic protoporphyria, or EPP.[1] The patent’s practical strength depends on whether a competing product uses the same peptide, a delivery system releasing it for at least two days, and plasma concentrations within the claimed limits.

What does U.S. Patent 10,076,555 protect?

The patent protects methods of administering afamelanotide to induce melanogenesis or reduce UV radiation-induced skin damage when the treatment satisfies specific duration, dosage-form, and plasma-concentration limitations.

Claim element	Required limitation
Patient	Human subject
Active ingredient	[Nle4, D-Phe7]-alpha-MSH, commonly called afamelanotide
Primary therapeutic result	Induction of melanogenesis by melanocytes in epidermal tissue
Alternative therapeutic result	Reduction of UV radiation-induced skin damage
Delivery duration	Release for at least two days
Plasma exposure	No more than 10 ng/mL for at least 24 hours
Narrower plasma exposure	No more than 2 ng/mL
Dosage form	Delivery system, including extended-release formulation, rod or implant
Route	Subcutaneous administration
Quantity	Up to 20 mg; 5 mg or more; or 10 mg to 20 mg
Composition range	5% to 60% afamelanotide

Claims 1 and 2 are the independent claims. Claim 1 covers melanogenesis. Claim 2 covers reduction of UV-induced skin damage. Claims 3 through 13 depend from claim 1, while claims 14 through 22 depend from claim 2.

How narrow are the independent claims?

The independent claims are narrow combination claims. A competing product would generally need to meet every limitation of the relevant claim to create literal infringement risk.

Claim 1 requires all of the following:

Administration to a human.
Use of the specifically identified alpha-MSH analogue.
An amount and treatment period sufficient to induce epidermal melanogenesis.
A delivery system releasing the analogue for at least two days.
Plasma concentrations not exceeding 10 ng/mL for at least 24 hours.

Claim 2 adds a different therapeutic-use limitation. The treatment must reduce the occurrence of UV radiation-induced skin damage, rather than merely induce pigmentation.

The exposure profile is central. A product using afamelanotide but producing plasma concentrations above 10 ng/mL for part of the claimed period may avoid literal infringement of claims 1 and 2, depending on the complete pharmacokinetic record. Conversely, a product with a lower concentration but immediate-release dosing could avoid the claims because the delivery system must release the peptide for at least two days.

What dependent claims expand the patent’s practical coverage?

The dependent claims create fallback positions around dose, formulation, route, duration, and concentration.

Dose and composition claims

Claims 3 and 14 cover a delivery system containing up to 20 mg of afamelanotide. Claims 5 and 16 cover 10 mg to 20 mg. Claims 4 and 15 recite “from 5 mg” without stating an upper endpoint. Read in the context of claim 3 or 14, those claims may be interpreted as requiring at least 5 mg while remaining subject to the 20 mg ceiling. Standing alone, the wording creates a potential indefiniteness and claim-construction issue.

Claim 11 covers a delivery system containing 5% to 60% afamelanotide. This limitation may be important for implant composition disputes because it focuses on the drug’s percentage of the delivery system rather than the total implant mass.

Duration claims

Claim 6 requires release for at least four days. Claim 7 requires release for at least six days. Claims 17 and 19 provide corresponding protection for the UV-damage method.

These claims are narrower than the two-day limitation but may be useful against products designed to approximate a week-long implant profile.

Plasma concentration claims

Claim 8 requires plasma levels not exceeding 2 ng/mL. Claim 18 imposes the same limit for the UV-damage method.

This limitation is materially narrower than the 10 ng/mL ceiling in claims 1 and 2. A defendant may dispute whether the claimed concentration is measured as total afamelanotide, unbound drug, a metabolite, a mean concentration, or the maximum concentration during the relevant period. The patent’s specification and prosecution history would control that interpretation.

Dosage-form and route claims

Claim 12 requires subcutaneous administration. Claim 13 specifies a rod or implant. Claim 21 covers an extended-release formulation. Claims 20 and 22 impose corresponding limitations for the UV-damage method.

These claims align closely with Scenesse’s subcutaneous implant presentation, although patent infringement depends on the specific product and treatment protocol rather than the commercial name alone.

What is the likely patent expiration date?

The patent appears to belong to the afamelanotide melanogenesis patent family with a June 3, 2008 priority date. On a standard 20-year patent term calculation, the base expiration date is June 3, 2029, subject to any patent-term adjustment, terminal disclaimer, patent-term extension, or other USPTO-record event.[2]

Event	Date or period
Earliest reported priority	June 3, 2008
Patent issued	September 18, 2018
Standard base expiration	June 3, 2029
FDA approval of Scenesse	October 8, 2019
FDA orphan-drug exclusivity	Generally through October 8, 2026
FDA new-chemical-entity exclusivity	Generally through October 8, 2024

The patent expiration date is separate from FDA regulatory exclusivity. Orphan-drug exclusivity can block FDA approval of the same drug for the same indication even when a patent does not block approval. Patent expiration can occur after regulatory exclusivity has ended.

A definitive term analysis requires the USPTO patent record, including any terminal disclaimer and patent-term adjustment. The patent’s commercial blocking position should therefore be assessed using the recorded expiration date rather than the priority-date calculation alone.

What is the Orange Book status of afamelanotide?

Scenesse is an FDA-approved afamelanotide implant for the prevention of phototoxic reactions in adult patients with EPP.[1] The FDA Orange Book is the relevant source for listed patents and approved-product exclusivity.[3]

The key regulatory distinction is between:

The FDA-approved product and indication.
The patents listed for the product.
The claims in U.S. Patent 10,076,555.
Any later patents covering formulation, manufacturing, delivery, or additional uses.

A patent covering a treatment method may be listed in the Orange Book if it claims an approved method of use and satisfies FDA listing requirements. Listing does not establish validity or infringement. It gives an ANDA applicant an opportunity to submit a Paragraph IV certification if the applicant contends that the listed patent is invalid, unenforceable, or not infringed.[4]

When does afamelanotide lose exclusivity?

Afamelanotide has multiple forms of exclusivity, and they end on different dates.

Patent exclusivity

The relevant patent family has a standard base term extending to approximately June 2029, subject to the official USPTO term calculation. Patent protection can cover use of the drug even after FDA orphan exclusivity has expired.

Orphan-drug exclusivity

Scenesse received approval for EPP, an orphan indication. Orphan-drug exclusivity generally lasts seven years from approval, placing the expected end of the original period in October 2026.[1] This exclusivity blocks approval of the same drug for the same disease or condition unless an exception applies.

Orphan exclusivity does not prevent approval of a different drug, a different active ingredient, or potentially a different use outside the protected orphan indication.

New chemical entity exclusivity

The FDA granted five years of new-chemical-entity exclusivity for the approved active ingredient. That period generally ended in October 2024. NCE exclusivity primarily limits the timing of ANDA submissions and does not eliminate later patent-based challenges.

Are Paragraph IV challenges likely?

An ANDA applicant seeking approval of a generic afamelanotide product could challenge listed patents through Paragraph IV certifications. The applicant would need to address both the drug product and the listed method-of-use patents.

A credible Paragraph IV strategy could attack the patent on several grounds:

Challenge theory	Relevance to Patent 10,076,555
Noninfringement	Product does not use the claimed peptide, release period, route, or plasma profile
Anticipation	Earlier disclosure allegedly contains every claim limitation
Obviousness	Afamelanotide, implants, melanogenesis, and pharmacokinetic targets allegedly make the combination obvious
Indefiniteness	Terms such as “effective amount and time,” “releases,” or “not exceeding” allegedly lack objective boundaries
Written description	Specification may not support the full scope of all dosage, concentration, and delivery-system combinations
Enablement	The patent may not enable the full claimed range without undue experimentation
Improper listing	Patent may not properly claim the approved method or may not qualify for Orange Book listing

The strongest noninfringement path would involve a product that uses a different active ingredient, an immediate-release formulation, an administration interval shorter than two days, or a plasma profile exceeding the claimed ceiling. The strongest validity challenge would likely focus on the combination of known afamelanotide pharmacology with known sustained-release implants and the objective concentration limits.

How strong is the patent estate for Scenesse?

The patent estate is strongest against a close substitute for the approved Scenesse product: the same peptide, administered subcutaneously through an implant or extended-release system, with sustained exposure over multiple days.

It is weaker against products that alter one or more of the following:

Active peptide sequence.
Delivery route.
Release duration.
Plasma concentration profile.
Treatment indication.
Implant composition.
Manufacturing process.
Dose and treatment interval.

The claims do not appear to cover the entire chemical class of alpha-MSH analogues. They identify [Nle4, D-Phe7]-alpha-MSH specifically. A competing melanocortin agonist with a different sequence would require a separate infringement analysis and may fall outside the literal scope of these claims.

What manufacturing and intellectual-property barriers exist?

The commercial barrier is not limited to the active ingredient. A competitor would need to reproduce a clinically acceptable long-acting peptide delivery system with controlled release, stability, sterility, dose uniformity, and reliable pharmacokinetics.

Potential manufacturing barriers include:

Peptide synthesis and impurity control.
Stability of the peptide during implant manufacture and storage.
Uniform release from a rod or implant.
Sterilization without loss of peptide potency.
Reproducible plasma exposure below the claimed threshold.
Scale-up of the implant manufacturing process.
Clinical evidence supporting the same or a different indication.

A competitor may also face separate patents covering implant materials, manufacturing methods, peptide formulations, analytical methods, or clinical uses. Those rights must be mapped independently from Patent 10,076,555.

What licensing deals affect the patent landscape?

The claims supplied do not establish ownership, licensing, sublicensing, or royalty arrangements. Commercial rights to afamelanotide have involved development and commercialization by Clinuvel Pharmaceuticals and predecessor entities, but the existence of a corporate commercialization relationship does not establish the scope of any patent license.

A transaction-level analysis should distinguish:

Ownership of Patent 10,076,555.
Exclusive rights to afamelanotide.
Rights limited to EPP.
Rights covering other photodermatoses or cosmetic pigmentation.
Rights to implant technology.
Territory-specific sublicenses.
Manufacturing licenses.

Patent ownership and product commercialization rights can reside with different entities.

Which companies are challenging afamelanotide exclusivity?

The supplied claims identify no Paragraph IV filer, ANDA applicant, inter partes review petitioner, or patent-litigation defendant. Patent 10,076,555 itself does not establish that a challenge has been filed.

For business purposes, the relevant potential challengers include generic-drug companies with peptide manufacturing capability, specialty pharmaceutical companies developing melanocortin agonists, and implant manufacturers seeking to supply a competing afamelanotide product.

A biosimilar pathway is generally not the expected route. Afamelanotide is a synthetic peptide drug rather than a therapeutic protein ordinarily regulated through the 351(k) biosimilar pathway. A competing sponsor would more likely pursue an ANDA if the product qualifies as pharmaceutically equivalent, or a 505(b)(2) application if it relies on a different formulation, delivery system, dosing regimen, or clinical bridge.[5]

What generic launch scenarios exist?

Scenario 1: Paragraph IV launch after patent challenge

A generic sponsor could file an ANDA with a Paragraph IV certification and trigger patent litigation. A 30-month stay may apply if the patent holder brings a timely infringement action under the Hatch-Waxman framework.[4]

Scenario 2: Carve-out of the patented method

If the approved labeling contains an indication or method covered by a listed patent, an ANDA applicant may attempt a section viii labeling carve-out. This strategy is difficult where the claimed use is closely connected to the product’s principal clinical indication.

Scenario 3: 505(b)(2) product

A sponsor could develop a different implant, dose, release profile, or administration schedule. That route may avoid some method claims while creating new clinical, formulation, and patent risks.

Scenario 4: Post-expiration launch

A company could defer launch until the relevant patent term ends. This reduces litigation risk but sacrifices first-mover opportunity and may allow the incumbent to secure additional formulation or method patents.

How does Patent 10,076,555 compare with a conventional formulation patent?

Patent 10,076,555 is primarily a method-of-treatment and pharmacokinetic-profile patent. It does not read like a conventional composition-of-matter patent covering the afamelanotide molecule itself.

Patent type	Typical protected subject matter	Relevance here
Composition of matter	New molecule or peptide sequence	Narrow relevance because the claim identifies a known analogue
Method of use	Treatment of a condition or physiological effect	Core structure of claims 1 and 2
Formulation	Excipients, dosage form, stability, release matrix	Reflected in claims 11, 13 and 21, but not the full estate
Device or implant	Implant structure or delivery mechanism	Relevant to rods and subcutaneous systems
Manufacturing	Synthesis, loading, sterilization, release testing	Separate potential barrier
Regulatory exclusivity	FDA approval-based market protection	Separate from patent scope

What patent litigation affects the product?

The claim text alone does not identify a litigation docket, settlement, consent judgment, or Paragraph IV notice involving Patent 10,076,555. A litigation assessment must distinguish this patent from other members of the afamelanotide family and from disputes involving unrelated melanocortin products.

If litigation arises, the central factual disputes are likely to include:

Whether the accused product uses [Nle4, D-Phe7]-alpha-MSH.
Whether its delivery system releases the peptide for at least two days.
Whether plasma concentration remains below 10 ng/mL or 2 ng/mL.
Whether the relevant treatment induces epidermal melanogenesis.
Whether the accused product reduces UV-induced skin damage.
Whether the claims are definite and enabled.
Whether the patent is properly listed for the approved product.

Key Takeaways

U.S. Patent 10,076,555 covers narrow methods using afamelanotide with sustained release and low plasma exposure.
Claims 1 and 2 require at least two days of release and plasma levels no higher than 10 ng/mL for at least 24 hours.
The patent is particularly relevant to subcutaneous rod or implant products resembling Scenesse.
Claims 8 and 18 narrow the plasma limit to 2 ng/mL.
Claims 13, 20, 21 and 22 target implant and extended-release delivery systems.
The apparent base patent term runs to approximately June 3, 2029, subject to the official USPTO term record.
FDA orphan exclusivity for Scenesse generally runs through October 2026, while five-year NCE exclusivity generally ended in October 2024.
A competing afamelanotide product could face Paragraph IV litigation if the patent is listed for the reference product.
A different melanocortin analogue, immediate-release product, alternative route, or materially different pharmacokinetic profile may provide noninfringement positions.
The principal commercial risk lies in reproducing the same active peptide and sustained-release exposure profile, not merely in treating pigmentation or photoprotection.

FAQs About U.S. Patent 10,076,555

Does U.S. Patent 10,076,555 cover all afamelanotide products?

No. The claims require a specific alpha-MSH analogue, a human treatment, sustained release for at least two days, and defined plasma exposure.

Does the patent cover cosmetic tanning?

Not expressly. The claims focus on induction of melanogenesis and reduction of UV-induced skin damage in a human subject. Cosmetic use would require separate analysis of claim construction and the specific treatment protocol.

Can a different alpha-MSH analogue avoid the patent?

Potentially. The claims identify [Nle4, D-Phe7]-alpha-MSH. A different peptide sequence may avoid literal infringement, although a doctrine-of-equivalents analysis could remain relevant.

Is Scenesse a biologic for biosimilar purposes?

Afamelanotide is a synthetic peptide drug. A competing sponsor would more commonly evaluate the ANDA or 505(b)(2) pathways rather than relying on the standard biosimilar pathway.

Does patent expiration automatically permit immediate generic launch?

No. FDA exclusivity, other Orange Book patents, regulatory approval requirements, manufacturing rights, and separate formulation or delivery patents can affect launch timing even after one patent expires.

References

U.S. Food and Drug Administration. (2019). Scenesse (afamelanotide) implant: Prescribing information. FDA.
U.S. Patent and Trademark Office. (2018). U.S. Patent No. 10,076,555, methods for inducing melanogenesis. USPTO.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.
21 U.S.C. § 355(j); 35 U.S.C. § 271(e).
U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005269244	⤷ Start Trial
Canada	2575866	⤷ Start Trial
China	101076314	⤷ Start Trial
Denmark	1789076	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,076,555

Summary for Patent: 10,076,555